Adjuvant low-dose aspirin does not improve unselected stage III colorectal cancer outcomes

CHICAGO — Low-dose aspirin during adjuvant chemotherapy did not significantly reduce risk for recurrence among unselected patients with stage III colorectal cancer, according to randomized trial data presented at ASCO Annual Meeting.However, lead author Atsuo Takashima, MD, PhD, gastrointestinal oncologist at National Cancer Center Hospital in Japan, and colleagues plan further subgroup

Raccontata dahealio.com